- Home
- VREX vs FENC Comparison
VREX vs FENC Comparison
Compare VREX & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VREX | FENC |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.2M | 372.4M |
| IPO Year | 2016 | 2010 |
Fundamental Metrics
Financial Performance| Metric | VREX | FENC |
|---|---|---|
| Price | $18.50 | $10.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $16.67 | $14.50 |
| AVG Volume (30 Days) | ★ 634.2K | 217.1K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.23 | 0.06 |
| Revenue | ★ $811,000,000.00 | $44,642,000.00 |
| Revenue This Year | $5.35 | $65.12 |
| Revenue Next Year | $3.88 | $41.08 |
| P/E Ratio | ★ $80.30 | $177.00 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.09 | $5.65 |
| 52 Week High | $18.63 | $13.25 |
Technical Indicators
Market Signals| Indicator | VREX | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 81.02 | 43.79 |
| Support Level | $12.00 | $9.84 |
| Resistance Level | $18.63 | $11.28 |
| Average True Range (ATR) | 0.05 | 0.48 |
| MACD | -0.19 | -0.10 |
| Stochastic Oscillator | 50.00 | 24.01 |
Price Performance
Historical ComparisonAbout VREX Varex Imaging Corporation
Varex Imaging Corp Designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, detectors, ionization chambers, high-voltage connectors, software, collimators, generators, exposure control devices, and heat exchangers.. The company operates through two segments: Medical, the key revenue driver, providing X-ray imaging components and accessories for healthcare applications, and Industrial, which provides Linatron X-ray accelerators, X-ray tubes, flat panel detectors, high-voltage connectors, and coolers for non-medical use. Geographically, it generates the majority of its revenue from Europe, the Middle East, and Africa (EMEA), with the rest coming from the Americas and Asia Pacific.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.